Net Investment Income (Loss)
The Company’s net investment income totaled $0.03 million and $0.4 million, or $0.04 and $0.63 per average unit, respectively, for the three and nine months ended September 30, 2022. The Company’s net investment loss totaled $0.1 million and $0.8 million, or $0.23 and $4.06 per average unit, respectively, for the three months ended September 30, 2021 and the period January 5, 2021 (commencement of operations) to September 30, 2021.
Net Realized Loss
The Company had investment sales and prepayments totaling approximately $0.3 million and $4.7 million, respectively, for the three and nine months ended September 30, 2022. Net realized loss over the same periods totaled $5 thousand and $11 thousand, respectively. The Company had investment sales and prepayments totaling approximately $3.5 million and $3.9 million, respectively, for the three months ended September 30, 2021 and the period January 5, 2021 (commencement of operations) to September 30, 2021. Net realized loss over the same periods totaled $2 thousand.
Net Change in Unrealized Gain (Loss)
For the three and nine months ended September 30, 2022, net change in unrealized gain (loss) on the Company’s assets totaled $142 thousand and $187 thousand, respectively. Net unrealized gain for the three and nine months ended September 30, 2022 was primarily due to appreciation on our investment in Arcutis Biotherapeutics, Inc., among others. For the three months ended September 30, 2021 and the period January 5, 2021 (commencement of operations) to September 30, 2021, net change in unrealized gain (loss) on the Company’s assets totaled ($29) thousand and $28 thousand. Net unrealized loss for the three months ended September 30, 21 was due to the reversal of previously recognized unrealized appreciation on MMIT Holdings, LLC. Net unrealized gain for the period January 5, 2021 (commencement of operations) to September 30, 2021 was due to appreciation on the value of our investment in BayMark Health Services, Inc.
Net Increase (Decrease) in Unitholders’ Capital Resulting From Operations
For the three and nine months ended September 30, 2022, the Company had a net increase in Unitholders’ capital resulting from operations of $165 thousand and $608 thousand, respectively. For the same periods, income per average unit was $0.24 and $0.89, respectively. For the three months ended September 30, 2021 and the period January 5, 2021 (commencement of operations) to September 30, 2021, the Company had a net decrease in Unitholders’ capital resulting from operations of $96 thousand and $777 thousand, respectively. For the same periods, loss per average unit was $0.34 and $3.93, respectively.
Financial Condition, Liquidity and Capital Resources
Our primary uses of cash are for (i) investments in portfolio companies and other investments to comply with certain portfolio RIC diversification requirements, (ii) the cost of operations (including paying the Adviser), (iii) debt service of any borrowings, and (iv) cash distributions to our Unitholders.
Equity
During the period January 5, 2021 (commencement of operations) to September 30, 2022, on a net basis, the Company sold and issued 682,427 common units at an average price of $22.71 per unit, for net proceeds of $15.5 million. All of our outstanding units were issued and sold in reliance upon the available exemptions from registration requirements of Section 4(a)(2) of the Securities Act. Unfunded equity capital commitments totaled $68.4 million at September 30, 2022.
39